Cover Image
市場調查報告書

Dynavax Technologies Corporation的產品平台分析

Dynavax Technologies Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251511
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Dynavax Technologies Corporation的產品平台分析 Dynavax Technologies Corporation - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 42 Pages
簡介

Dynavax Technologies Corporation是位於臨床現階段的生物醫藥品企業。該公司致力於感染疾病及發炎性疾病治療用醫藥品的藥物研究與開發。

本報告提供Dynavax Technologies Corporation上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Dynavax Technologies Corporation的基本資料

Dynavax Technologies Corporation概要

  • 主要資訊
  • 企業資料

Dynavax Technologies Corporation:R&D概要

  • 主要的治療範圍

Dynavax Technologies Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Dynavax Technologies Corporation:開發中產品概況

  • 位於最終階段的開發中產品
    • 申請未通過/被撤消的產品/聯合治療模式
    • 位於第三階段的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Dynavax Technologies Corporation:藥物簡介

  • B型肝炎疫苗
  • AZ-1419
  • DV-1179
  • SD-101
  • DV-230
  • 以人類乳突病毒(HPV)感染疾病的TLR9作為標的基因重組蛋白質

Dynavax Technologies Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Dynavax Technologies Corporation:最近的開發平台趨勢

Dynavax Technologies Corporation:暫停中的計劃

Dynavax Technologies Corporation:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • Amb a 1-ISS Conjugate
    • Cytovax

Dynavax Technologies Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07873CDB

Summary

Global Markets Direct's, 'Dynavax Technologies Corporation - Product Pipeline Review - 2015', provides an overview of the Dynavax Technologies Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dynavax Technologies Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dynavax Technologies Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dynavax Technologies Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dynavax Technologies Corporation's pipeline products

Reasons to buy

  • Evaluate Dynavax Technologies Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dynavax Technologies Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dynavax Technologies Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dynavax Technologies Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dynavax Technologies Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dynavax Technologies Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dynavax Technologies Corporation Snapshot
    • Dynavax Technologies Corporation Overview
    • Key Information
    • Key Facts
  • Dynavax Technologies Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Dynavax Technologies Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Dynavax Technologies Corporation - Pipeline Products Glance
    • Dynavax Technologies Corporation - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Dynavax Technologies Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Dynavax Technologies Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Dynavax Technologies Corporation - Drug Profiles
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SD-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-1419
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DV-1179
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DV-230
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dynavax Technologies Corporation - Pipeline Analysis
    • Dynavax Technologies Corporation - Pipeline Products by Target
    • Dynavax Technologies Corporation - Pipeline Products by Route of Administration
    • Dynavax Technologies Corporation - Pipeline Products by Molecule Type
    • Dynavax Technologies Corporation - Pipeline Products by Mechanism of Action
  • Dynavax Technologies Corporation - Recent Pipeline Updates
  • Dynavax Technologies Corporation - Dormant Projects
  • Dynavax Technologies Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Amb a 1-ISS Conjugate
      • Cytovax
  • Dynavax Technologies Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dynavax Technologies Corporation, Key Information
  • Dynavax Technologies Corporation, Key Facts
  • Dynavax Technologies Corporation - Pipeline by Indication, 2015
  • Dynavax Technologies Corporation - Pipeline by Stage of Development, 2015
  • Dynavax Technologies Corporation - Monotherapy Products in Pipeline, 2015
  • Dynavax Technologies Corporation - Partnered Products in Pipeline, 2015
  • Dynavax Technologies Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • Dynavax Technologies Corporation - Filing rejected/Withdrawn, 2015
  • Dynavax Technologies Corporation - Phase III, 2015
  • Dynavax Technologies Corporation - Phase I, 2015
  • Dynavax Technologies Corporation - Preclinical, 2015
  • Dynavax Technologies Corporation - Pipeline by Target, 2015
  • Dynavax Technologies Corporation - Pipeline by Route of Administration, 2015
  • Dynavax Technologies Corporation - Pipeline by Molecule Type, 2015
  • Dynavax Technologies Corporation - Pipeline Products by Mechanism of Action, 2015
  • Dynavax Technologies Corporation - Recent Pipeline Updates, 2015
  • Dynavax Technologies Corporation - Dormant Developmental Projects,2015
  • Dynavax Technologies Corporation - Discontinued Pipeline Products, 2015
  • Dynavax Technologies Corporation, Subsidiaries

List of Figures

  • Dynavax Technologies Corporation - Pipeline by Top 10 Indication, 2015
  • Dynavax Technologies Corporation - Pipeline by Stage of Development, 2015
  • Dynavax Technologies Corporation - Monotherapy Products in Pipeline, 2015
  • Dynavax Technologies Corporation - Pipeline by Top 10 Target, 2015
  • Dynavax Technologies Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Dynavax Technologies Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Dynavax Technologies Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top